Pharmaceuticals & Therapeutics

BridgeBio Oncology's new drug candidate BBO-10203 could redefine cancer therapy by avoiding a key toxicity, unlocking a vast market.

A small biotech is challenging oncology's giants with a drug that targets cancer's core weakness, offering new hope to the sickest lung cancer patients.

A new campaign tackles undiagnosed kidney disease. But is it just public health, or a savvy strategy to reshape a multi-billion dollar market?

A regulatory filing reveals a key investor's move as Alkermes' $2.1B bid for Avadel and its blockbuster narcolepsy drug, LUMRYZ, nears its final act.

With a new patent, this biotech targets the massive orthopedics market. But can its novel fibroblast therapy overcome steep financial and clinical hurdles?

New data shows Kazia's paxalisib dismantles metastatic drivers and reignites immunity, signaling a strategic disruption in advanced breast cancer treatment.

A new partnership between Telix and Varian aims to fuse precision diagnostics with adaptive radiotherapy, a strategic move set to disrupt the cancer care market.

MediWound's burn treatment now prevents traumatic tattoos from blasts and accidents, signaling a major strategic expansion and a new era in trauma care.

Providence Care's new CEO is a former therapist. Can his clinical insight solve market challenges and deliver on a private equity growth plan?

Following stellar clinical data, Terns Pharmaceuticals' upsized $650M offering signals massive investor confidence and funds its push to disrupt the CML market.

A new oral drug could eliminate the dangerous side effects of CAR T-Cell therapy, potentially making the breakthrough cancer treatment safer and more accessible.

Beyond a simple product launch, a strategic acquisition is fueling innovations in drug delivery that could transform patient care for millions worldwide.

Tempus AI's research at a key symposium shows its AI-driven edge, turning vast patient data into a powerful asset that could reshape oncology and investor outlooks.

A fierce bidding war for Avadel Pharmaceuticals reveals the high value of its key drug, as filings from giants like State Street highlight M&A transparency.

A new patent for its lead cancer drug in Japan is more than a legal win; it's a strategic move to secure a future market into the 2040s.

Animal health giant Elanco is restructuring its global footprint, betting its future on a U.S.-centric innovation pipeline and blockbuster pet health drugs.

With validated Phase 1b data, ONL Therapeutics' novel drug aims to protect vision cells, not just slow disease, in a challenge to current GA therapies.

With stellar clinical data for its TERN-701 drug, Terns is raising massive capital to challenge Novartis and reshape the multi-billion-dollar CML market.

Guangdong Jiaying Pharma is leveraging its unique Hakka heritage to enter the global market. But can ancient wisdom navigate modern regulatory and corporate hurdles?

Protara Therapeutics secured a $75M offering to advance its promising cancer drug, TARA-002, signaling renewed investor confidence in biotech innovation.